Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment
- PMID: 1582503
Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment
Abstract
Steroid hormone receptors have been evaluated as independent prognostic factors as well as predictive factors for endocrine manipulation in the clinical management of breast cancer. The contribution of each receptor or combinations of different receptors remains controversial. In cytosols from 224 patients with operable breast cancer (stages I & II), estrogen receptor (ER), progesterone receptor (PgR) and androgen receptor (AR) content have been measured. An improved AR-assay has been used in order to circumvent some of the problems inherent in other methods. In this study, 91.1% of the patients were classified as AR 'positive' (i.e. greater than or equal to 10 pmol/g). The steroid hormone receptors were significantly correlated (P less than 0.001). Taking the median value of AR as cut-off (50.5 pmol/g), a significantly higher incidence (P = 0.004) of node negative patients was found in the group with a lower AR content. In a multivariate analysis the AR category (median value used as cut-off) was shown to be an independent predictor of the likelihood of axillary metastases (P = 0.001). AR category, however, did not reveal any significant prognostic information concerning relapse free survival. A subpopulation of node positive patients with ER positive tumors, have been included in a randomized trial on the role of tamoxifen as an adjuvant treatment compared with no endocrine treatment. In a multivariate analysis, PgR status was shown to be a single independent prognostic factor (P = 0.016) for relapse free survival in patients with a lower AR content (less than median value). The improved AR assay used in the present study may provide a basis for more correct estimation of the AR content in an individual tumor. The present study suggests that AR analysis and the use of a well-chosen cut-off level may add information about tumor biology to increase our understanding of breast cancer biology and treatment.
Similar articles
-
Triple-negative breast cancer: role of the androgen receptor.Cancer J. 2010 Jan-Feb;16(1):62-5. doi: 10.1097/PPO.0b013e3181ce4ae1. Cancer J. 2010. PMID: 20164692 Review.
-
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.Neoplasma. 2000;47(2):107-13. Neoplasma. 2000. PMID: 10985476 Clinical Trial.
-
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.Clin Cancer Res. 1995 Feb;1(2):189-98. Clin Cancer Res. 1995. PMID: 9815973
-
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.Cancer Res. 1979 May;39(5):1447-54. Cancer Res. 1979. PMID: 427788
-
The use of steroïd hormone receptors in the treatment of human breast cancer: a review.Bull Cancer. 1979;66(3):203-9. Bull Cancer. 1979. PMID: 385079 Review.
Cited by
-
Prevalence of Androgen Receptor in Invasive Breast Cancer and Its Association with Clinicopathologic Features in East Azarbaijan Province of Iran: A Cross-Sectional Study.Int J Hematol Oncol Stem Cell Res. 2023 Jul 1;17(3):186-193. doi: 10.18502/ijhoscr.v17i3.13308. Int J Hematol Oncol Stem Cell Res. 2023. PMID: 37817975 Free PMC article.
-
Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.Biomedicines. 2023 Aug 7;11(8):2215. doi: 10.3390/biomedicines11082215. Biomedicines. 2023. PMID: 37626712 Free PMC article. Review.
-
Androgen receptor in breast cancer: The "5W" questions.Front Endocrinol (Lausanne). 2022 Aug 30;13:977331. doi: 10.3389/fendo.2022.977331. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36111296 Free PMC article. Review.
-
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770. doi: 10.1007/s00280-019-03908-0. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367790 Free PMC article.
-
Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan.Ann Saudi Med. 2018 Sep-Oct;38(5):326-335. doi: 10.5144/0256-4947.2018.326. Ann Saudi Med. 2018. PMID: 30284987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials